630 results about "Combination Medication" patented technology

The invention relates to application of a combined pharmaceutical composition in preparation of a medicine for resisting transforming follicular lymphoma. Active components in the combined pharmaceutical composition comprise a first component and a second component, the first component is selected from any one or a combination of at least two of sitagliflozin, pharmaceutically acceptable salt, isomer, solvate and metabolite of sitagliflozin; and the second component is selected from any one or a combination of at least two of chidamide, pharmaceutically acceptable salts, isomers, solvates and metabolites of the chidamide. Research finds that the combined use of the two active components not only can reduce the dosage of each drug and improve the medication safety, but also has the effect of improving or treating convertible follicular lymphoma more remarkably than that of a single drug active component, and plays a role in synergistic promotion. The invention provides an effective drug combination strategy for improvement or treatment of convertible follicular lymphoma, and has very significant significance.

The invention relates to the technical field of biological medicines, in particular to a polypeptide for broad-spectrum inhibition of influenza viruses and application of the polypeptide in prevention and / or treatment of influenza virus infection. The polypeptide for broad-spectrum inhibition of influenza virus comprises the following selections: (1) an amino acid sequence as shown in SEQ ID NO: 1; (2) an amino acid sequence having at least 50% homology with the amino acid sequence shown in (1); (3) amino acid sequences obtained by replacing and / or deleting and / or increasing at least one amino acid residue at any position in the amino acid sequences shown in (1) and (2); and (4) modifying the amino acid sequences shown in (1), (2) and (3) to obtain amino acid sequences. The invention comprises a peptide sequence, a derivative, a peptide composition and independent or combined application in prevention or treatment of anti-influenza viruses, such as combined medication of the polypeptide or the derivative of the polypeptide and other anti-influenza drugs.

The invention relates to the technical field of intelligent medical treatment, and discloses a medical large model driven cross-department collaborative prescription generation method and system. According to the method, electronic medical records of patients and prescription data of multiple departments are acquired, key information is structurally extracted to generate directional vectors, and transfer learning and fine adjustment are performed by using historical conflict cases and a drug knowledge graph based on a medical basic large model and an AI chip, so that a collaborative prescription model is constructed. The model can identify drug incompatibility and dosage risks among departments and generate a prescription suggestion set. A doctor can dynamically correct a prescription based on feedback, a collaborative report containing a medication time sequence, a monitoring index and an emergency scheme is generated after multiple rounds of collaborative optimization, and the safety and effectiveness of multi-department combined medication of complex diseases are remarkably improved.

The invention discloses a drug-combined anticancer composition and application of the composition in preparation of anticancer drugs. According to the present invention, the drug combination composition comprises the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate, the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate provide the synergistic effect, and compared with the single PARP inhibitor, the drug combination composition has characteristics of high stomach cancer sensitivity, significant gastric cancer efficiency improving, and wide application prospect. The Amlodipine in the drug combination composition provided by the invention enhances the curative effect of the PARP inhibitor Olaparib on the gastric cancer.

The invention provides application of osimertinib and saquinavir in preparation of a medicine for treating EGFR-TKI drug-resistant non-small cell lung cancer, and belongs to the technical field of biological medicine. According to the invention, osimertinib and saquinavir are combined for medication, the inhibition rate of EGFR-TKI resistant non-small cell lung cancer is obviously higher than that of single medication, the combined medication of osimertinib and saquinavir has a synergistic inhibition effect, and the inhibition efficiency is higher than that of osimertinib and rimonabant. The experimental result of the invention provides a theoretical basis for clinical drug combination of osimertinib and saquinavir and an effective scheme of NSCLC for treating EGFR-TKI drug resistance, and has a wide application prospect in the field of medicine and pharmacology.

The invention discloses a method for determining drug combination, which comprises the following steps: constructing a calculation model, and constructing the calculation model according to a response surface method; obtaining a reaction value, and inputting the reaction value to the calculation model, the reaction value including a factor main effect and a multi-factor interaction effect; a regression algorithm adapted to the relationship between the reaction variable and the reaction value; the optimal solution of the drug combination is obtained, the obtaining mode of the optimal solution is obtained from the regression algorithm, and the method further comprises a corresponding device and a storage medium. The method has the advantages that the calculation model for drug combination is constructed through the response surface method, the optimal solution of drug combination is obtained through calculation by inputting the factors, and compared with an exhaustion mode in the prior art, the efficiency is higher, and more time, manpower and resource consumption are saved.

A drug combination of purinostat mesylate and an analog thereof for preventing and treating multiple myeloma, and the use thereof. Specifically, provided is a three-drug or four-drug combination of purinostat mesylate and an analog thereof, dexamethasone and other drug, which drug combination has significantly enhanced synergistic anti-tumor activity in vitro and in vivo, synergistically inhibits the expression of the key survival protein in multiple myeloma, is superior to existing clinical combination regimens, and has no significant toxic side effects. In addition, the drug combination significantly down-regulates the expression of CDK6, and overcomes the drug resistance to an immunomodulator. In particular, the three-drug combination of puisostat mesylate, a glucocorticoid and an immunomodulator has an excellent prevention and treatment effect on multiple myeloma, especially relapsed / refractory multiple myeloma.

The invention relates to an application of a combination of fludarabine and temozolomide in treatment of brain glioma. A drug combination composition comprises fludarabine and temozolomide. The temozolomide and the fludarabine are combined for use, so that a synergistic interaction effect is generated on treatment of the brain glioma, and the effect is obviously better than that of single use of the temozolomide and the fludarabine. Therefore, the pharmaceutical composition for treating the brain glioma, provided by the invention, can be used for remarkably inhibiting the growth of the brain glioma cells and prolonging the lifetime of a patient, and a brand new strategy and thought are provided for the treatment of the brain glioma.

Purinostat mesylate (PM) for preventing and treating diffuse large B-cell lymphoma (DLBCL), an analogue thereof, a drug for combined use, and the use. PM exhibits excellent in-vivo and in-vitro anti-tumor therapeutic effects on DLBCL (DEL and DHL) subtypes with poor prognosis, DLBCL subtypes having TP53 deletion and mutation combined with a plurality of poor prognosis gene mutations, and DLBCL having TP53 mutation with double expressors, which are superior to that of most existing DLBCL clinical therapy plans. A doublet or triplet therapy of PM with rituximab, R-CHOP, venetoclax and R-CHP also exhibits excellent in-vivo therapeutic effects against DLBCL and a plurality of subtypes. Thus, PM and the drug for combined use have an important clinical significance for the DLBCL and a plurality of subtypes.

The invention discloses a drug-resistant marker for treating prostatic cancer olaparib and application of the drug-resistant marker, and relates to the technical field of medicine, and the marker is a PCAR1 gene. Research finds that the PCAR1 gene is remarkably and highly expressed in prostate cancer Olaparil drug-resistant cells and clinical drug-resistant samples, and can be used as a key marker for judging the drug resistance of prostate cancer patients to Olaparil. By detecting the expression level of the PCAR1 gene, the treatment reaction of a patient to the olaparil can be effectively predicted, and a basis is provided for clinically and accurately selecting a treatment scheme. Meanwhile, the specific siRNA designed aiming at the PCAR1 gene can obviously inhibit the expression of the PCAR1 gene, and can effectively reduce the drug resistance of cancer cells to olaparione, promote the apoptosis of the cancer cells and inhibit the proliferation of the cancer cells when being combined with the olaparione for use. Based on the siRNA, the invention prepares a pharmaceutical composition containing the siRNA and olaparil, and provides a new drug combination scheme for the treatment of prostatic cancer.

The invention relates to an application of an intervention SNRK-MTA1 signal channel axis in preparation of a non-small cell lung cancer targeted therapy drug. The nucleotide sequences of the mRNA of the SNRK gene and the mRNA of the MTA1 gene are respectively as shown in SEQ ID NO.1-2. The invention innovatively provides a strategy for treating the non-small cell lung cancer through double-target combined intervention. According to the strategy, SNRK gene expression is improved through exogenous gene overexpression plasmids, and meanwhile MTA1 gene expression is silenced through the siRNA technology. In a non-small cell lung cancer model, the strategy of combined application of the SNRK-OE plasmid and siMTA1 can specifically up-regulate the SNRK mRNA level and knock down the MTA1 mRNA level at the same time, and the combined strategy shows a better anti-tumor effect than single intervention, and can more effectively inhibit the growth and migration of tumor cells. Based on the discovery, the SNRK-MTA1 signal pathway axis can be developed into a novel therapeutic target for non-small cell lung cancer, and is used for designing a drug combination scheme or a composite targeted drug.

The invention relates to a combined pharmaceutical composition for improving or treating follicular lymphoma, which is characterized in that the active components of the combined pharmaceutical composition consist of a first active component and a second active component, the first active component is selected from any one or a combination of at least two of simvastatin, pharmaceutically acceptable salt, isomer, solvate and metabolite of simvastatin; the second active component is selected from any one or a combination of at least two of dovirisad, pharmaceutically acceptable salt, isomer, solvate and metabolite of dovirisad. The research finds that the simvastatin and the dovirisail not only can reduce the dosage of the simvastatin or the dovirisail and improve the medication safety, but also have the effect of improving or treating follicular lymphoma more remarkably than that of single simvastatin or dovirisail, and play a synergistic promotion effect.

The invention discloses a medicine composition containing homoharringtonine and application of the medicine composition in preparation of an anti-HIV (human immunodeficiency virus) medicine. The medicine composition is composed of the homoharringtonine and a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor, the nucleoside reverse transcriptase inhibitor is selected from one of the compounds of zidovudine, lamivudine and abacavir, and the non-nucleoside reverse transcriptase inhibitor is selected from one of the compounds of nevirapine, efavirenz and rilpivirine. The pharmaceutical composition has a remarkable synergistic effect on treatment of HIV, the curative effect of the medicine is improved, the dosage of a single medicine is reduced, the toxic and side effects are reduced, the generation of viruses can be remarkably inhibited by combined medication, a very remarkable antiviral effect is generated, and the treatment current situation of HIV-1, especially middle and advanced AIDS, is improved.

The invention discloses a tumor stem cell targeting virus-like drug carrier as well as a preparation method and application thereof. The drug carrier provided by the invention can improve the cell uptake efficiency by simulating the physical surface characteristics of a biological system, and can directly target tumor stem cells. Besides, the drug carrier has targeting property, so that healthy tissues can be protected, the side effects of the loaded drug such as PTC209 in high-dose independent use are obviously reduced, the reaction to tumor stem cells is effectively enhanced, tumor proliferation and metastasis are inhibited, and the drug resistance of drug combination such as cis-platinum is reduced.

The invention provides a drug combination composition for tumor chemotherapy. The drug combination composition comprises a safe and effective dose of a platinum chemotherapeutic drug and a safe and effective dose of an NAMPT inhibitor. Compared with a single platinum chemotherapeutic drug, the combined drug composition provided by the invention has higher sensitivity to cancers such as liver cancer, gastric cancer, colorectal cancer, lung cancer, cervical cancer, kidney cancer, pancreatic cancer, breast cancer and the like, the effective rate is remarkably improved, and the toxic and side effects are remarkably reduced, so that the combined drug composition has a wide application prospect.

The present invention relates to a use of THBS1 as a novel combination drug target that can overcome drug resistance of a targeted anticancer agent. A THBS1 inhibitor according to the present invention inhibits the drug resistance of a target anticancer agent and thus increases an anticancer effect when administered in combination with a target anticancer agent. Accordingly, the present invention can overcome resistance to a targeted anticancer agent and increase a treatment success rate of anticancer drugs for cancer patients, thereby suggesting new possibilities for treatment strategies using targeted anticancer drugs and contributing to the realization of precision medicine.

The invention relates to an application of an AMPK inhibitor and ferroptosis inducer combined drug in tumor treatment, in particular to an application of a ferroptosis inducer (RSL3) combined AMPK inhibitor (Compound C) in preparation of a drug for tumor treatment, and belongs to the technical field of biological medicine. In-vivo and in-vitro experiments prove that the combination of a ferroptosis inducer (RSL3) and an AMPK inhibitor (Compound C) drug can significantly inhibit the proliferation of non-small cell lung cancer cells with high expression of MORC2. The drug combination exerts significant synergistic interaction, and has more effective tumor treatment effect than a single drug. Therefore, the combination of the ferroptosis inducer and the cell metabolism inhibitor serves as a new potential clinical treatment strategy, and a new thought is provided for tumor treatment of high-expression MORC2.

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.

The invention discloses a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The composition comprises an IGF2BP3 inhibitor and a platinum chemotherapeutic drug. According to the combined medication scheme, the IGF2BP3 function is inhibited to block an ATF4 survival promoting signal channel mediated by the IGF2BP3 function, a synergistic effect is generated with a DNA damage mechanism of platinum drugs, the anti-tumor effect can be remarkably enhanced, chemotherapy drug resistance can be effectively reversed, toxic and side effects are expected to be reduced, and the application prospect is wide. And a new strategy is provided for overcoming the treatment problem of the non-small cell lung cancer, especially platinum-resistant non-small cell lung cancer.

The invention relates to a combined traditional Chinese medicine composition for treating tumors by improving a tumor immune microenvironment and application thereof. The combined traditional Chinese medicine composition comprises rhein and hesperidin. Rheinic acid and hesperidin have stronger antitumor activity than single components in combined application, and the combined pharmaceutical composition can significantly inhibit the growth of cancer-related fibroblasts, reduce CCL2 secreted by cancer-related adipocytes and increase infiltration of CD8 + T cells at tumor sites, so that the growth of tumors is significantly inhibited, and the antitumor effect is improved. And a new method and thought are provided for combined treatment of cancers.

The invention belongs to the field of biological medicines, and finds and verifies that taquinimod or pharmaceutically acceptable salts thereof can be used for preparing medicines for treating endometriosis for the first time, and is particularly suitable for progestogen-resistant, recurrent or deep infiltration type endometriosis. The action mechanism of the taquinimod is as follows: the taquinimod can down-regulate the expression of S100A9 protein and reduce the infiltration of S100A9 + macrophages by inhibiting an NF-kappa B signal channel so as to further inhibit the expression of a vascular endothelial growth factor receptor 1 (VEGFR1) and a matrix metalloproteinase 2 (MMP2), finally block pathological angiogenesis and inhibit the growth of ectopic lesions. Animal experiments show that the taquinimod can significantly reduce the number and weight of nidus of a mouse model with endometriosis. The invention provides a brand-new non-hormone treatment choice with a clear action mechanism for clinical application, provides a pharmaceutical composition containing a specific dosage and a drug combination scheme, and has an important clinical value.

The present invention belongs to the field of drug research and development, and specifically discloses a method, storage chip and device for efficiently evaluating the efficacy of in vitro combined drug therapy. The present invention directly solves the problems of complexity and high cost of experiments and data processing in the existing drug development process by adopting an AI model and a simplified experimental mode. The AI ​​model optimizes concentration selection based on historical drug data, thereby reducing redundant concentrations and unnecessary number of experiments in the experiment, and improving the sensitivity and reliability of the evaluation. By simplifying the experimental design to single drug concentration point testing and a 3x3 combined drug matrix, the complexity and cost of the experiment are significantly reduced, while the speed of data processing and analysis is accelerated. The method disclosed in the present invention avoids excessive combined drug pre-testing by directly conducting single drug and 3x3 matrix combined drug testing, which can not only more effectively identify potential synergies between drugs, but also provide more accurate and practical data to support future clinical research.

The invention discloses a 2, 5-diketopiperazine compound with an anti-tumor effect and application of the 2, 5-diketopiperazine compound in preparation of a medicine for treating and / or preventing neutropenia, and the 2, 5-diketopiperazine compound is novel in structure, has good activity and water solubility, and can be used for preparing medicines for treating and / or preventing neutropenia. The defects of poor water solubility of the ponabulin, unfavorable patent medicine and difficult clinical administration can be overcome. The 2, 5-diketopiperazine compound as shown in the formula (I) or the pharmaceutically acceptable salt thereof can be used for treating and / or preventing neutropenia and improving toxic and side effects of clinical tumor treatment, and has an anti-tumor effect at the same time. The invention also discloses application of drug combination of the compound and a granulocyte colony stimulating factor (G-CSF) biological agent in drugs for treating and / or preventing neutropenia. # imgabs0 #

The invention provides a pharmaceutical composition, glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a pharmaceutical composition. The pharmaceutical composition comprises glycyrrhizic acid and polymyxin B. According to the pharmaceutical composition, the inhibition effect on MRSA is enhanced through drug combination, the use of polymyxin B is reduced through the synergistic effect, and the development pressure of antibiotic drug resistance is relieved. According to the hydrogel formed by crosslinking the glycyrrhizic acid and the calcium chloride, the glycyrrhizic acid and the calcium chloride are crosslinked to form the hydrogel, and the calcium chloride is introduced into a glycyrrhizic acid system to increase the mechanical strength of the glycyrrhizic acid hydrogel, so that the glycyrrhizic acid hydrogel can be better attached to a wound. The invention provides a glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel and a preparation method of the glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel. The hydrogel does not contain any inert carrier component at all, the drug loading rate of 100% is achieved, and adverse reactions possibly caused by a traditional carrier system are effectively avoided.

The invention relates to a pharmaceutical composition for treating acute myelogenous leukemia. The pharmaceutical composition comprises lonidamine and a GPX4 inhibitor. The invention also relates to application of the pharmaceutical composition in preparation of drugs for resisting acute myelogenous leukemia cells. Aiming at an oxidation-antioxidation defense system of AML tumor cells, lonidamine and the GPX4 inhibitor are creatively combined for use, the inhibition rate of lonidamine and the GPX4 inhibitor on the AML cells is remarkably higher than that of independent medication, and the combination of lonidamine and the GPX4 inhibitor can synergistically inhibit the activity of the AML cells, induce mitochondria damage of the AML cells and promote ferroptosis of the AML cells, so that the purpose of treating the AML is achieved.

The invention relates to a recombinant complement protein and application thereof in preparation of anti-leukemia drugs, and belongs to the technical field of biological medicines. The invention discloses a method for treating acute leukemia by single drug, namely injecting recombinant C1QBP protein, which has a remarkable effect on treating acute leukemia, can be used for remarkably inhibiting proliferation of leukemia cells in marrow, spleen and peripheral blood of a hematopoietic system and also inhibiting infiltration of the leukemia cells in extramedullary organs (skin and the like), so that the whole-body tumor load is reduced, and the curative effect of treating acute leukemia is improved. The lifetime of leukemia mice is obviously prolonged. The recombinant C1QBP protein is combined with a clinical first-line chemotherapy regimen for use, has a synergistic effect, has a stronger effect of inhibiting leukemia cell proliferation compared with a single chemotherapy drug, can significantly prolong the lifetime of leukemia mice, and plays a role in reducing toxicity and enhancing efficacy. The invention proves that the complement C1Q binding protein has the effect of treating leukemia for the first time, provides a preparation method and a drug combination scheme, and has relatively high clinical transformation prospect and application value.

The invention discloses an anti-tumor combined pharmaceutical composition and application thereof, and belongs to the technical field of biological medicine. The combined pharmaceutical composition comprises an OTUD4 inhibitor and a ferroptosis inducer or regorafenib which serve as active ingredients, and the OTUD4 inhibitor inhibits expression of OTUD4 in a targeted mode or causes function deficiency of OTUD4 and promotes occurrence of ferroptosis in tumor cells. The combined pharmaceutical composition provided by the invention more effectively inhibits tumor growth by synergistically increasing the oxidative stress level in cells, thereby playing a stronger anti-tumor effect. The combined treatment scheme provided by the invention provides a new thought for tumor treatment, and particularly in patients ineffective or drug-resistant to single-drug treatment, targeted inhibition of OTUD4 and regorafenib can effectively overcome drug resistance and significantly inhibit tumor growth.

The invention belongs to the technical field of biological medicines, and particularly relates to application of quercetin combined with curcumin in preparation of an anti-allergic reaction medicine. Through a large number of researches, the inventor finds that combined administration of quercetin and curcumin with a specific concentration can effectively inhibit mast cell degranulation, and the inhibition rate of mast cell degranulation reaches 90% or more, so that I-type anaphylaxis mediated by immune globulin E is inhibited, especially systemic anaphylaxis, and the curative effect is good. The compound can be used for preparing anti-anaphylaxis drugs. The drug combination scheme provided by the invention has important significance and wide application prospect in drugs for treating or preventing anaphylactic reactions.

The present application relates to a pharmaceutical combination of a PARP7 inhibitor combined medication, and a use thereof in treating tumors. The pharmaceutical combination comprises: a first active ingredient PARP7 inhibitor, a second active ingredient CTLA-4 inhibitor or platinum complex, and optionally a third active ingredient PD-1 inhibitor or PD-L1 inhibitor.

The invention relates to internet-of-things digital intelligent medicine and medicine interaction virtual-real fusion terminal equipment, and aims to solve the problem of medicine selection deviation caused by insufficient medical knowledge of a user in a traditional medicine purchasing process. The device obtains user symptoms through multi-mode interaction (voice, touch screen and video), generates a combined medication scheme based on a cloud medical knowledge base and a medicine database, and introduces a doctor, pharmacist and licensed pharmacist auditing mechanism to guarantee scientific medication and safe medication of the user. The system supports four payment modes and two medicine taking modes (self-pick-up / delivery), realizes full-process intelligentization from symptom analysis to medicine delivery, and adapts to full-process digitalization from body organ part-part symptom to medicine delivery in local dialects. According to the method, the user can be guided to accurately purchase medicines with scientific and safe medication according to the disease symptoms, the correspondence between the medicines purchased by the user and the disease symptoms is improved, the risk of wrong medication of the user is reduced, and the accuracy of scientific and professional medication is improved.